Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsINJECTIONGeneric

UNASYN

AMPICILLIN SODIUM; SULBACTAM SODIUM

Standard Dose
EQ 500MG BASE/VIAL;EQ 250MG BASE/VIAL
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary

Approval overview UNASYN is listed in Drugs@FDA under application 050608 (NDA).

Review priority: STANDARD Marketing status: Discontinued Active ingredient AMPICILLIN SODIUM; SULBACTAM SODIUM Form and strength INJECTABLE;INJECTION - EQ 500MG BASE/VIAL;EQ 250MG BASE/VIAL Sponsor PFIZER Submission history Latest submission status date: 2025-11-05 00:00:00.

Structured Monograph

Clinical summary

Approval overview UNASYN is listed in Drugs@FDA under application 050608 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient AMPICILLIN SODIUM; SULBACTAM SODIUM Form and strength INJECTABLE;INJECTION - EQ 500MG BASE/VIAL;EQ 250MG BASE/VIAL Sponsor PFIZER Submission history Latest submission status date: 2025-11-05 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Discontinued
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.